Donepezil in the treatment of progressive supranuclear palsy

G. Fabbrini, P. Barbanti, V. Bonifati, C. Colosimo, M. Gasparini, N. Vanacore, G. Meco

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Objectives - To evaluate the effect of 3 month therapy with donepezil, a centrally acting cholinesterase inhibitor, on cognitive performances, motor function and daily living activities in progressive supranuclear palsy (PSP). Materials and methods - Six patients with a diagnosis of PSP were evaluated at baseline and after 3 months of treatment with donepezil, 10 mg given at bedtime. Cognitive functions, motor symptoms and daily activities were evaluated by means of appropriate rating scales. Results - Donepezil was not effective on cognitive dysfunction and did not change ratings of daily living. Parkinsonian symptoms were unaffected by donepezil treatment. Conclusions - Cholinergic replacement therapy alone is not likely to improve symptoms in a disorder characterized by a more widespread impairment of monoaminergic systems. Larger studies may be necessary to confirm the lack of effect of donepezil in this disorder.

Original languageEnglish
Pages (from-to)123-125
Number of pages3
JournalActa Neurologica Scandinavica
Volume103
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

Progressive Supranuclear Palsy
Therapeutics
Cholinesterase Inhibitors
Activities of Daily Living
Cognition
Cholinergic Agents
donepezil

Keywords

  • Donepezil
  • Progressive supranuclear palsy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Donepezil in the treatment of progressive supranuclear palsy. / Fabbrini, G.; Barbanti, P.; Bonifati, V.; Colosimo, C.; Gasparini, M.; Vanacore, N.; Meco, G.

In: Acta Neurologica Scandinavica, Vol. 103, No. 2, 2001, p. 123-125.

Research output: Contribution to journalArticle

Fabbrini, G. ; Barbanti, P. ; Bonifati, V. ; Colosimo, C. ; Gasparini, M. ; Vanacore, N. ; Meco, G. / Donepezil in the treatment of progressive supranuclear palsy. In: Acta Neurologica Scandinavica. 2001 ; Vol. 103, No. 2. pp. 123-125.
@article{a88042933174452baa8b8e77ae76602f,
title = "Donepezil in the treatment of progressive supranuclear palsy",
abstract = "Objectives - To evaluate the effect of 3 month therapy with donepezil, a centrally acting cholinesterase inhibitor, on cognitive performances, motor function and daily living activities in progressive supranuclear palsy (PSP). Materials and methods - Six patients with a diagnosis of PSP were evaluated at baseline and after 3 months of treatment with donepezil, 10 mg given at bedtime. Cognitive functions, motor symptoms and daily activities were evaluated by means of appropriate rating scales. Results - Donepezil was not effective on cognitive dysfunction and did not change ratings of daily living. Parkinsonian symptoms were unaffected by donepezil treatment. Conclusions - Cholinergic replacement therapy alone is not likely to improve symptoms in a disorder characterized by a more widespread impairment of monoaminergic systems. Larger studies may be necessary to confirm the lack of effect of donepezil in this disorder.",
keywords = "Donepezil, Progressive supranuclear palsy",
author = "G. Fabbrini and P. Barbanti and V. Bonifati and C. Colosimo and M. Gasparini and N. Vanacore and G. Meco",
year = "2001",
doi = "10.1034/j.1600-0404.2001.103002123.x",
language = "English",
volume = "103",
pages = "123--125",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley Blackwell",
number = "2",

}

TY - JOUR

T1 - Donepezil in the treatment of progressive supranuclear palsy

AU - Fabbrini, G.

AU - Barbanti, P.

AU - Bonifati, V.

AU - Colosimo, C.

AU - Gasparini, M.

AU - Vanacore, N.

AU - Meco, G.

PY - 2001

Y1 - 2001

N2 - Objectives - To evaluate the effect of 3 month therapy with donepezil, a centrally acting cholinesterase inhibitor, on cognitive performances, motor function and daily living activities in progressive supranuclear palsy (PSP). Materials and methods - Six patients with a diagnosis of PSP were evaluated at baseline and after 3 months of treatment with donepezil, 10 mg given at bedtime. Cognitive functions, motor symptoms and daily activities were evaluated by means of appropriate rating scales. Results - Donepezil was not effective on cognitive dysfunction and did not change ratings of daily living. Parkinsonian symptoms were unaffected by donepezil treatment. Conclusions - Cholinergic replacement therapy alone is not likely to improve symptoms in a disorder characterized by a more widespread impairment of monoaminergic systems. Larger studies may be necessary to confirm the lack of effect of donepezil in this disorder.

AB - Objectives - To evaluate the effect of 3 month therapy with donepezil, a centrally acting cholinesterase inhibitor, on cognitive performances, motor function and daily living activities in progressive supranuclear palsy (PSP). Materials and methods - Six patients with a diagnosis of PSP were evaluated at baseline and after 3 months of treatment with donepezil, 10 mg given at bedtime. Cognitive functions, motor symptoms and daily activities were evaluated by means of appropriate rating scales. Results - Donepezil was not effective on cognitive dysfunction and did not change ratings of daily living. Parkinsonian symptoms were unaffected by donepezil treatment. Conclusions - Cholinergic replacement therapy alone is not likely to improve symptoms in a disorder characterized by a more widespread impairment of monoaminergic systems. Larger studies may be necessary to confirm the lack of effect of donepezil in this disorder.

KW - Donepezil

KW - Progressive supranuclear palsy

UR - http://www.scopus.com/inward/record.url?scp=0035154265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035154265&partnerID=8YFLogxK

U2 - 10.1034/j.1600-0404.2001.103002123.x

DO - 10.1034/j.1600-0404.2001.103002123.x

M3 - Article

C2 - 11227131

AN - SCOPUS:0035154265

VL - 103

SP - 123

EP - 125

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 2

ER -